MedTrace Logo

Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy

NCT01022671 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2016-01-28

No results posted yet for this study

Summary

A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Belotecan

3.0 mg/m2, Day 1, 8, 15 every 4 weeks

Sponsors & Collaborators

  • Asan Medical Center

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • Seoul National University Hospital

    collaborator OTHER

  • Ulsan University Hospital

    collaborator OTHER

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-02-28
Completion
2010-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01022671 on ClinicalTrials.gov